88,112 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Purchased by American Century Companies Inc.

American Century Companies Inc. bought a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 88,112 shares of the company's stock, valued at approximately $319,000. American Century Companies Inc. owned 0.10% of Atyr PHARMA as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ATYR. Alterna Wealth Management Inc. acquired a new stake in Atyr PHARMA in the fourth quarter worth about $36,000. Victory Capital Management Inc. bought a new position in shares of Atyr PHARMA in the 4th quarter valued at about $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA in the fourth quarter valued at approximately $39,000. JPMorgan Chase & Co. grew its stake in shares of Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after purchasing an additional 10,754 shares during the period. Finally, Farther Finance Advisors LLC bought a new stake in Atyr PHARMA in the fourth quarter valued at about $88,000. Institutional investors own 61.72% of the company's stock.

Atyr PHARMA Stock Up 2.6 %

ATYR stock traded up $0.08 during trading hours on Friday, reaching $3.10. 801,662 shares of the stock were exchanged, compared to its average volume of 893,943. The firm's 50-day moving average is $3.38 and its 200-day moving average is $3.30. Atyr PHARMA INC has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a market cap of $275.46 million, a price-to-earnings ratio of -3.30 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. On average, equities research analysts expect that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ATYR shares. Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Friday, March 14th. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an "overweight" rating on the stock. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.